Inhibikase therapeutics, inc. IKT.US Overview
IKT AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
IKT Current Performance
-3.80%
Inhibikase therapeutics, inc.
-0.34%
Avg of Sector
-1.60%
S&P500
IKT Key Information
IKT Revenue by Segments
Browsing restrictions can be lifted for a fee.
IKT Net Income
Browsing restrictions can be lifted for a fee.
IKT Cash Flow
Browsing restrictions can be lifted for a fee.
IKT Profit Margin
Browsing restrictions can be lifted for a fee.
IKT PE Ratio River
Browsing restrictions can be lifted for a fee.
IKT Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
IKT Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
IKT Profile
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Price of IKT
IKT FAQ
When is IKT's latest earnings report released?
The most recent financial report for Inhibikase therapeutics, inc. (IKT) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IKT's short-term business performance and financial health. For the latest updates on IKT's earnings releases, visit this page regularly.
How much cash does IKT have?
At the end of the period, Inhibikase therapeutics, inc. (IKT) held Total Cash and Cash Equivalents of 73.44M, accounting for 0.78 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is IKT's EPS continuing to grow?
According to the past four quarterly reports, Inhibikase therapeutics, inc. (IKT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.15. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of IKT?
Inhibikase therapeutics, inc. (IKT)'s Free Cash Flow (FCF) for the period is -4.12M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 6.46% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.